Drug companies increasingly frustrated with the Government over surging NHS clawbacks
Drug companies increasingly frustrated with the Government over surging NHS clawbacks
Copy link
Its decision comes as the industry says there is a lack of government investment and as the US pressures firms to invest there.
Drug company chairman calls for change to ‘appalling’ rules on NHS drug prices
AstraZeneca has paused a planned investment in the U.K., which had been set to create 1,000 jobs.
Drugmaker had stalled large-scale projects in England but has now pledged investment at two sites, announced by Keir Starmer
AstraZeneca chief executive Pascal Soriot has thanked the Government ‘for their efforts to improve access for patients’
Merck criticises ‘successive UK governments’ as it cancels King’s Cross development
AstraZeneca pauses £200m Cambridge investment
AstraZeneca pauses $270 million investment in Britain
Big pharma firms have paused nearly £2bn in UK investments this year
How the UK fell out with big pharma
Pharma firms pile pressure on the UK as Trump's drug pricing order looms
US urged UK to offer better drug pricing deal to pharma companies
Merck scraps £1bn expansion in the UK over lack of state investment
